- In June 2022, Priothera, a late-stage biotechnology company, presented initial clinical data on its S1P receptor modulator, mocravimod (KRP203), for patients with hematological malignancies undergoing allogeneic hematopoietic stem cell transplantation (HSCT). The data was shared at the European Hematology Association (EHA) 2022 Congress in Vienna, Austria, from June 9-12, 2022
- In May 2022, Priothera received U.S. Food and Drug Administration (FDA) clearance for an investigational new drug (IND) to initiate a Phase 2b/3 study of mocravimod in Acute Myeloid Leukemia (AML) patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT)
- In December 2021, the U.S. Food and Drug Administration approved a treatment to prevent acute graft-versus-host disease (GVHD) in patients aged 2 years or older receiving a hematopoietic stem cell transplant from a matched or single-HLA-mismatched unrelated donor
- In August 2021, Magenta Biosciences announced a spin-off collaboration with bluebird bio to develop HSPC-based gene therapies for genetic diseases. The exact date of the announcement was not specified
- In July 2020, Gamida Cell announced positive results from a Phase 3 clinical trial of NiCord, an investigational product. The trial demonstrated improved overall survival and faster neutrophil engraftment compared to standard umbilical cord blood transplantation
Frequently Asked Questions
Companies such as Novartis (Switzerland), Gilead Sciences (U.S.), Bristol-Myers Squibb (U.S.), AbbVie (U.S.), Kite Pharma (U.S.), Celgene (U.S.), Beckman Coulter (U.S.), StemCell Technologies (Canada), Thermo Fisher Scientific (U.S.), Invitrogen (U.S.) are the major companies in the hematopoietic stem cell transplantation market.
In May 2022, Priothera received U.S. Food and Drug Administration (FDA) clearance for an investigational new drug (IND) to initiate a Phase 2b/3 study of mocravimod in Acute Myeloid Leukemia (AML) patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). In August 2021, Magenta Biosciences announced a spin-off collaboration with bluebird bio to develop HSPC-based gene therapies for genetic diseases.
The countries covered in the hematopoietic stem cell transplantation market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, and rest of Middle East and Africa.
